苯丁酸氮芥-话题@MedSci

#苯丁酸氮芥#

6篇内容 | 667人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1604523, encodeId=ba0a1604523d5, content=<a href='/topic/show?id=20608e033a6' target=_blank style='color:#2F92EE;'>#苯丁酸氮芥#</a>, objectTitle=ASH 2015：Gazyva联合苯丁酸氮芥一线治疗CLL后4年内无需治疗, objectType=article, longId=60416, objectId=efc1604161b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efc1604161b, replyNumber=0, likeNumber=28, createdTime=2015-12-10, rootId=0, userName=zengjiayao, userId=fc2819208964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efc1604161b, moduleTitle=ASH 2015：Gazyva联合苯丁酸氮芥一线治疗CLL后4年内无需治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efc1604161b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1604522, encodeId=2d3c1604522ce, content=<a href='/topic/show?id=20608e033a6' target=_blank style='color:#2F92EE;'>#苯丁酸氮芥#</a>, objectTitle=NEJM：对于处置慢性CLL患者，Ibrutinib优于苯丁酸氮芥, objectType=article, longId=60350, objectId=a90660350f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a90660350f4, replyNumber=0, likeNumber=28, createdTime=2015-12-08, rootId=0, userName=zengjiayao, userId=fc2819208964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a90660350f4, moduleTitle=NEJM：对于处置慢性CLL患者，Ibrutinib优于苯丁酸氮芥, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a90660350f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1604521, encodeId=4071160452160, content=<a href='/topic/show?id=20608e033a6' target=_blank style='color:#2F92EE;'>#苯丁酸氮芥#</a>, objectTitle=The Lancet：苯丁酸氮芥和奥法木单抗联合治疗是CLL的更好的选择, objectType=article, longId=49347, objectId=2a5e4934e74, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a5e4934e74, replyNumber=0, likeNumber=0, createdTime=2015-04-16, rootId=0, userName=zengjiayao, userId=fc2819208964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a5e4934e74, moduleTitle=The Lancet：苯丁酸氮芥和奥法木单抗联合治疗是CLL的更好的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a5e4934e74)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1604520, encodeId=e13a160452047, content=<a href='/topic/show?id=20608e033a6' target=_blank style='color:#2F92EE;'>#苯丁酸氮芥#</a>, objectTitle=NEJM：Obinutuzumab加苯丁酸氮芥治疗CLL伴合并症者更有效, objectType=article, longId=29580, objectId=ec5a2958045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5a2958045, replyNumber=0, likeNumber=40, createdTime=2014-01-19, rootId=0, userName=zengjiayao, userId=fc2819208964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5a2958045, moduleTitle=NEJM：Obinutuzumab加苯丁酸氮芥治疗CLL伴合并症者更有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5a2958045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1604519, encodeId=b95f160451965, content=<a href='/topic/show?id=20608e033a6' target=_blank style='color:#2F92EE;'>#苯丁酸氮芥#</a>, objectTitle=FDA批准Gazyva与苯丁酸氮芥联合治疗慢性淋巴细胞白血病, objectType=article, longId=26357, objectId=0aed2635ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0aed2635ee7, replyNumber=0, likeNumber=40, createdTime=2013-11-09, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0aed2635ee7, moduleTitle=FDA批准Gazyva与苯丁酸氮芥联合治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0aed2635ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1604518, encodeId=5a18160451847, content=<a href='/topic/show?id=20608e033a6' target=_blank style='color:#2F92EE;'>#苯丁酸氮芥#</a>, objectTitle=ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存, objectType=article, longId=21187, objectId=ad0e2118ed1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad0e2118ed1, replyNumber=0, likeNumber=26, createdTime=2013-07-13, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad0e2118ed1, moduleTitle=ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad0e2118ed1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

苯丁酸氮芥

2020-05-29

zengjiayao (审核中...)

前往app查看评论内容

#苯丁酸氮芥#

ASH 2015：Gazyva联合苯丁酸氮芥一线治疗CLL后4年内无需治疗

2015-12-10

zengjiayao (审核中...)

前往app查看评论内容

#苯丁酸氮芥#

NEJM：对于处置慢性CLL患者，Ibrutinib优于苯丁酸氮芥

2015-12-08

zengjiayao (审核中...)

前往app查看评论内容

#苯丁酸氮芥#

The Lancet：苯丁酸氮芥和奥法木单抗联合治疗是CLL的更好的选择

2015-04-16

zengjiayao (审核中...)

前往app查看评论内容

#苯丁酸氮芥#

NEJM：Obinutuzumab加苯丁酸氮芥治疗CLL伴合并症者更有效

2014-01-19

医者仁心 (审核中...)

前往app查看评论内容

#苯丁酸氮芥#

FDA批准Gazyva与苯丁酸氮芥联合治疗慢性淋巴细胞白血病

2013-11-09

医者仁心 (审核中...)

前往app查看评论内容

#苯丁酸氮芥#

ICML2013：利妥昔单抗联合苯丁酸氮芥治疗MALT淋巴瘤可延长无事件生存

2013-07-13

科室
- - 订阅+
  - 更多科室
工具
服务